Lorvotuzumab mertansine

Lorvotuzumab mertansine ^?

Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	CD56
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	1008106-64-6^N
ATC code	None
UNII	0IVD6ASY0W^N
KEGG	D09927^N
Chemical data
Formula	?
N (what is this?) (verify)

Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate of lorvotuzumab linked to mertansine intended for CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer).^[1]^[2]

It has been granted Orphan drug status for Merkel cell carcinoma.^[3]

It has reported encouraging Phase II results for small-cell lung cancer.^[4]

References

^ Dimond (9 Mar 2010). "Antibody-Drug Conjugates Stage a Comeback".
^ ImmunoGen reports encouraging clinical data of IMGN901. News-medical.net. Retrieved on 2010-11-20.
^ http://www.news-medical.net/news/20100308/ImmunoGen-receives-FDA-orphan-drug-designation-for-IMGN901-compound-in-treatment-of-MCC.aspx
^ "ImmunoGen Announces Encouraging New Clinical Data With The Company’s IMGN901 Compound In The Treatment Of Small-Cell Lung Cancer". 2009.

Monoclonal antibodies for tumors

Tumor ("-t(u[m])-")

Human ("-tumu-")	Adecatumumab Cixutumumab Conatumumab Daratumumab Drozitumab Duligotumab Dusigitumab Figitumumab Ganitumab Glembatumumab vedotin Intetumumab Iratumumab Lexatumumab Lucatumumab Mapatumumab Narnatumab Necitumumab Ofatumumab Olaratumab Panitumumab Patritumab Pritumumab Radretumab Rilotumumab Robatumumab Teprotumumab Tovetumab Vantictumab Votumumab Zalutumumab "-melu-" (melanoma): Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab CC49 Detumomab Ibritumomab tiuxetan Minretumomab Mitumomab Moxetumomab pasudotox Naptumomab estafenatox Nofetumomab merpentan Pemtumomab^† Pintumomab Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Tenatumomab Tositumomab 3F8 "-govo-" (ovarian tumor): Abagovomab · Igovomab · Oregovomab "-pro-" (prostate tumor): Capromab pendetide "-colo-" (colonic tumor): Edrecolomab · Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab Bavituximab Brentuximab vedotin Cetuximab Ensituximab Futuximab Girentuximab Indatuximab ravtansine Margetuximab Rituximab Siltuximab Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Afutuzumab Alemtuzumab Bevacizumab Bivatuzumab mertansine Cantuzumab mertansine Cantuzumab ravtansine Citatuzumab bogatox Clivatuzumab tetraxetan Dacetuzumab Dalotuzumab Elotuzumab^† Etaracizumab Farletuzumab Ficlatuzumab Gemtuzumab ozogamicin Imgatuzumab Inotuzumab ozogamicin Labetuzumab Lintuzumab Lorvotuzumab mertansine Matuzumab^§ Milatuzumab Nimotuzumab Ocaratuzumab Onartuzumab Oportuzumab monatox Parsatuzumab Pertuzumab Sibrotuzumab Simtuzumab Tacatuzumab tetraxetan Tigatuzumab Trastuzumab Tucotuzumab celmoleukin Veltuzumab Vorsetuzumab mafodotin

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab Ertumaxomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

↑Jump back a section

Read in another language

This page is available in 1 language

Italiano

Last modified on 22 March 2013, at 00:14